Trial Profile
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 12 Dec 2023 Planned End Date changed from 30 Sep 2023 to 30 Dec 2042.
- 17 Sep 2023 Planned End Date changed from 1 Dec 2023 to 30 Sep 2023.
- 28 Apr 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.